Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing …
HJ Hwang, IS Sohn, ES Jin, YJ Bae - PLoS One, 2023 - journals.plos.org
Background Twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs)
may reduce drug adherence compared with once-daily dosing of NOACs in patients with …
may reduce drug adherence compared with once-daily dosing of NOACs in patients with …
Minimal Adherence Threshold to Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation to Reduce the Risk of Thromboembolism and Death …
M Grymonprez, S Steurbaut, A Capiau… - … Drugs and Therapy, 2023 - Springer
Purpose Poor adherence to non-vitamin K antagonist oral anticoagulants (NOACs) may
raise thromboembolic risks in patients with atrial fibrillation (AF). However, the minimal …
raise thromboembolic risks in patients with atrial fibrillation (AF). However, the minimal …
[HTML][HTML] Effect of structured educational intervention booklet regarding anticoagulation therapy on knowledge among patients undergoing mechanical valve …
M El Menem, NS Khalil, MS Ismaeel - Egyptian Nursing Journal, 2022 - journals.lww.com
Background Valvular heart diseases are the principal causes of morbidity and mortality
among patients with rheumatic heart diseases in Egypt. Management of these patients …
among patients with rheumatic heart diseases in Egypt. Management of these patients …
Methodological challenges in the comparative assessment of effectiveness and safety of oral anticoagulants in individuals with atrial fibrillation using administrative …
L Gubaidullina - 2023 - papyrus.bib.umontreal.ca
Atrial fibrillation (AF), the most common cardiac arrhythmia is a major risk factor for the
development of ischemic stroke. Direct oral anticoagulants (DOACs) replaced warfarin in …
development of ischemic stroke. Direct oral anticoagulants (DOACs) replaced warfarin in …
Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years
A Romagnoli, F Santoleri, A Costantini… - European Journal of …, 2024 - ejhp.bmj.com
Introduction Adherence to and persistence with long-term treatment with oral anticoagulants
play a significant role in preventing adverse events and mortality in patients with cardiac …
play a significant role in preventing adverse events and mortality in patients with cardiac …